WNCT: Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
FOX40 News: Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...
Please donate to The AFIB Report, using one of the two buttons below. A third donation method, beyond choosing either the Donate with PayPal or Donate with Credit/Debit card described elsewhere on this site, is for those who prefer to directly mail a check or money order to our business address at: The AFIB Report, A Non-Profit 501 (c) (3) Corporation, C/O Shannon Dickson, P.O. Box 1016 ...
THE AFIB REPORT was started in January of 2001 as a vehicle for sharing my findings with fellow afibbers. The LAF Forum Bulletin Board saw its first posting in September 2000 and now contains over 100,000 contributions from afibbers around the world.
It is well established that BNP and nt-pro-BNP levels are elevated in heart failure and that the degree of elevation is directly proportional to the seriousness of the failure. However, researchers at the Massachusetts General Hospital have reported that lone afibbers also have elevated nt-pro-BNP values even when in sinus rhythm. Their study involved 150 participants with lone atrial ...